1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Cognition Disorders in 16 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Chronic administration of low doses of MPTP resulted in animals with stable cognitive deficits without overt parkinsonian motor symptoms." | 1.32 | Differences in alpha7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys. ( Kulak, JM; Schneider, JS, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (25.00) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Tang, C | 1 |
| Liu, M | 1 |
| Zhou, Z | 1 |
| Li, H | 1 |
| Yang, C | 1 |
| Yang, L | 1 |
| Xiang, J | 1 |
| Castro, AA | 1 |
| Wiemes, BP | 1 |
| Matheus, FC | 1 |
| Lapa, FR | 1 |
| Viola, GG | 1 |
| Santos, AR | 1 |
| Tasca, CI | 1 |
| Prediger, RD | 2 |
| Fifel, K | 1 |
| Dkhissi-Benyahya, O | 1 |
| Cooper, HM | 1 |
| Ho, SC | 1 |
| Hsu, CC | 1 |
| Pawlak, CR | 1 |
| Tikhonova, MA | 1 |
| Lai, TJ | 1 |
| Amstislavskaya, TG | 1 |
| Ho, YJ | 1 |
| Pflibsen, L | 1 |
| Stang, KA | 1 |
| Sconce, MD | 1 |
| Wilson, VB | 1 |
| Hood, RL | 1 |
| Meshul, CK | 1 |
| Mitchell, SH | 1 |
| Aguiar, AS | 1 |
| Lopes, SC | 1 |
| Tristão, FS | 1 |
| Rial, D | 1 |
| de Oliveira, G | 1 |
| da Cunha, C | 2 |
| Raisman-Vozari, R | 1 |
| Moriguchi, S | 1 |
| Yabuki, Y | 1 |
| Fukunaga, K | 1 |
| Schneider, JS | 7 |
| Pioli, EY | 1 |
| Jianzhong, Y | 1 |
| Li, Q | 1 |
| Bezard, E | 1 |
| Kulak, JM | 1 |
| Braga, R | 1 |
| Kouzmine, I | 1 |
| Canteras, NS | 1 |
| Roeltgen, DP | 1 |
| Pope-Coleman, A | 1 |
| Tinker, JP | 1 |
| Van Velson, M | 1 |
| Menzaghi, F | 1 |
| Lloyd, GK | 1 |
| Wade, TV | 1 |
| Giardiniere, M | 1 |
| Morain, P | 1 |
| Taylor, JR | 1 |
| Elsworth, JD | 1 |
| Roth, RH | 1 |
| Collier, TJ | 1 |
| Sladek, JR | 1 |
| Redmond, DE | 1 |
16 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Cognition Disorders
| Article | Year |
|---|---|
Treadmill Exercise Alleviates Cognition Disorder by Activating the FNDC5: Dual Role of Integrin αV/β5 in Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Cognition | 2023 |
Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Analysis of Variance; Anim | 2013 |
Lack of long-term changes in circadian, locomotor, and cognitive functions in acute and chronic MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Circadian Rhythm; Cognition | 2013 |
Effects of ceftriaxone on the behavioral and neuronal changes in an MPTP-induced Parkinson's disease rat model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain; CA1 Region, Hipp | 2014 |
Executive function deficits and glutamatergic protein alterations in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Brain; Cognition Disord | 2015 |
Exercise Improves Cognitive Impairment and Dopamine Metabolism in MPTP-Treated Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Catale | 2016 |
Reduced calcium/calmodulin-dependent protein kinase II activity in the hippocampus is associated with impaired cognitive function in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Calcium-Calmodulin-Dependent Protein Kinase T | 2012 |
Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; C | 2013 |
Differences in alpha7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adaptation, Physiological; alpha7 Nicotinic Acetylchol | 2004 |
Lesion of the substantia nigra, pars compacta impairs delayed alternation in a Y-maze in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cognition Disorders; Denervation; Disease Mod | 2005 |
Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cognition Disorders; Discri | 1993 |
Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cognition Disorders; Discrimination Learning; | 1995 |
Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Attention; Cognition Disorders; Conditioning, | 1999 |
Expression of striatal preprotachykinin mRNA in symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys is related to parkinsonian motor signs.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Cognition Disorders; Corpus | 2001 |
Effects of the prolyl endopeptidase inhibitor S 17092 on cognitive deficits in chronic low dose MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cognition Disorders; Conditioning, Operant; D | 2002 |
Improvements in MPTP-induced object retrieval deficits and behavioral deficits after fetal nigral grafting in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Tissue Transplantation; Caudate Nucleus | 1990 |